Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #101 to #600.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Flexible tissues‏‎ (3 revisions)
  2. Guide to the System of Radiological Protection‏‎ (3 revisions)
  3. Autonomy‏‎ (3 revisions)
  4. Dose limit‏‎ (3 revisions)
  5. Target region‏‎ (3 revisions)
  6. Fluence‏‎ (3 revisions)
  7. Constancy test‏‎ (3 revisions)
  8. Dose‏‎ (3 revisions)
  9. Dose limits‏‎ (3 revisions)
  10. Fluoroscopically guided interventions‏‎ (3 revisions)
  11. Annual dose‏‎ (3 revisions)
  12. Potential exposure‏‎ (3 revisions)
  13. DS02‏‎ (3 revisions)
  14. Accountability‏‎ (3 revisions)
  15. X ray‏‎ (3 revisions)
  16. Half-life, physical‏‎ (3 revisions)
  17. Cell death‏‎ (3 revisions)
  18. Contamination‏‎ (3 revisions)
  19. Rigidity threshold‏‎ (3 revisions)
  20. Dose of record (E)‏‎ (3 revisions)
  21. Low Earth orbit‏‎ (3 revisions)
  22. Exponential survival curve‏‎ (3 revisions)
  23. Unsealed source‏‎ (3 revisions)
  24. Xerostomia‏‎ (3 revisions)
  25. Annual limit on intake‏‎ (3 revisions)
  26. Graded approach‏‎ (3 revisions)
  27. Public exposure‏‎ (3 revisions)
  28. Dose per content function‏‎ (3 revisions)
  29. Interphase death‏‎ (3 revisions)
  30. Equity‏‎ (3 revisions)
  31. Test‏‎ (3 revisions)
  32. Fractionation‏‎ (3 revisions)
  33. Uptake‏‎ (3 revisions)
  34. Active (red) bone marrow‏‎ (3 revisions)
  35. Utilitarian ethics‏‎ (3 revisions)
  36. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  37. Operational quantity‏‎ (3 revisions)
  38. Value judgement‏‎ (3 revisions)
  39. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  40. Coster-Kronig transition‏‎ (3 revisions)
  41. Valvular heart disease‏‎ (3 revisions)
  42. Gray‏‎ (3 revisions)
  43. Personal dose equivalent‏‎ (3 revisions)
  44. Principle of justification‏‎ (3 revisions)
  45. Radiofrequency ablation‏‎ (3 revisions)
  46. Emergency preparedness‏‎ (3 revisions)
  47. Absolute risk‏‎ (3 revisions)
  48. Virtue ethics‏‎ (3 revisions)
  49. Auger transition‏‎ (3 revisions)
  50. Bystander effect‏‎ (3 revisions)
  51. Iso-effect plots‏‎ (3 revisions)
  52. Emergency procedures‏‎ (3 revisions)
  53. Lifetime risk estimates‏‎ (3 revisions)
  54. Activity median thermodynamic diameter‏‎ (3 revisions)
  55. Voxel phantom‏‎ (3 revisions)
  56. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  57. Complex tissues‏‎ (3 revisions)
  58. Derived air concentration‏‎ (3 revisions)
  59. Dignity‏‎ (3 revisions)
  60. Isomers‏‎ (3 revisions)
  61. Employer‏‎ (3 revisions)
  62. Exposure to Radon at Home‏‎ (2 revisions)
  63. Transparency‏‎ (2 revisions)
  64. GATA binding protein 2‏‎ (2 revisions)
  65. Waste disposal‏‎ (2 revisions)
  66. Non-targeted effects‏‎ (2 revisions)
  67. Hormones‏‎ (2 revisions)
  68. Authorization‏‎ (2 revisions)
  69. Procedural values‏‎ (2 revisions)
  70. Clonogenic cells‏‎ (2 revisions)
  71. Curie‏‎ (2 revisions)
  72. Reproductive integrity‏‎ (2 revisions)
  73. Safety case‏‎ (2 revisions)
  74. Slow repair‏‎ (2 revisions)
  75. Effect Dose 50‏‎ (2 revisions)
  76. Isotropic geometry‏‎ (2 revisions)
  77. Endogeneous excretion‏‎ (2 revisions)
  78. Lineal energy‏‎ (2 revisions)
  79. Thyroid blocking‏‎ (2 revisions)
  80. Trapped particles‏‎ (2 revisions)
  81. Acute radiation syndrome‏‎ (2 revisions)
  82. Orphan source‏‎ (2 revisions)
  83. Hounsfield unit‏‎ (2 revisions)
  84. Authorized limit‏‎ (2 revisions)
  85. Planned exposure situation‏‎ (2 revisions)
  86. Progenitor cell‏‎ (2 revisions)
  87. Cardiac arrhythmias‏‎ (2 revisions)
  88. Radiation belt‏‎ (2 revisions - redirect page)
  89. Clonogenic survival‏‎ (2 revisions)
  90. Reasonableness‏‎ (2 revisions)
  91. Cytokines‏‎ (2 revisions)
  92. Residual dose‏‎ (2 revisions)
  93. Safety culture‏‎ (2 revisions)
  94. Solar cosmic radiation‏‎ (2 revisions)
  95. Inhalability‏‎ (2 revisions)
  96. Spontaneous fission‏‎ (2 revisions)
  97. Itinerant (radiation) worker‏‎ (2 revisions)
  98. Linear-non-threshold model‏‎ (2 revisions)
  99. Time factor‏‎ (2 revisions)
  100. Myocardial perfusion‏‎ (2 revisions)
  101. Adaptive response‏‎ (2 revisions)
  102. What is Radon?‏‎ (2 revisions)
  103. Alveolar-interstitial region‏‎ (2 revisions)
  104. Autoimmune disease‏‎ (2 revisions)
  105. Platelet-derived growth factor‏‎ (2 revisions)
  106. ICRP Publication 118‏‎ (2 revisions)
  107. Cardiac valve diseases‏‎ (2 revisions)
  108. Radiation modifier‏‎ (2 revisions)
  109. Radiological protection principles‏‎ (2 revisions)
  110. Respiratory protection‏‎ (2 revisions)
  111. Disposal‏‎ (2 revisions)
  112. Scintigraphy‏‎ (2 revisions)
  113. Dose criteria‏‎ (2 revisions)
  114. Solar cycle‏‎ (2 revisions)
  115. Inner bremsstrahlung‏‎ (2 revisions)
  116. Environmental exposure‏‎ (2 revisions)
  117. Systemic model‏‎ (2 revisions)
  118. Linear-quadratic dose response model‏‎ (2 revisions)
  119. Exempt waste‏‎ (2 revisions)
  120. Tissue equivalent material‏‎ (2 revisions)
  121. Myocardial stress test‏‎ (2 revisions)
  122. Oversight‏‎ (2 revisions)
  123. Projected dose‏‎ (2 revisions)
  124. Co-expertise‏‎ (2 revisions)
  125. Radionuclides of natural origin‏‎ (2 revisions)
  126. Connective tissue‏‎ (2 revisions)
  127. Recovery (cellular or tissue)‏‎ (2 revisions)
  128. DRL process‏‎ (2 revisions)
  129. Retrievability‏‎ (2 revisions)
  130. Immune system‏‎ (2 revisions)
  131. Institutional control‏‎ (2 revisions)
  132. Stakeholder‏‎ (2 revisions)
  133. Environmental radiation protection‏‎ (2 revisions)
  134. Tachycardia‏‎ (2 revisions)
  135. Exemption level‏‎ (2 revisions)
  136. Existing exposure situation‏‎ (2 revisions)
  137. Gastroschisis‏‎ (2 revisions)
  138. Worker‏‎ (2 revisions)
  139. Nuclear track detectors‏‎ (2 revisions)
  140. Angiogenesis‏‎ (2 revisions)
  141. Hyperbaric oxygen‏‎ (2 revisions)
  142. Bioturbation‏‎ (2 revisions)
  143. Cardioverter-defibrillator‏‎ (2 revisions)
  144. Radiation safety officer‏‎ (2 revisions)
  145. Radioresponsiveness‏‎ (2 revisions)
  146. Consequential late effects‏‎ (2 revisions)
  147. Recovery responder‏‎ (2 revisions)
  148. Reversibility‏‎ (2 revisions)
  149. In vivo radiobioassay‏‎ (2 revisions)
  150. Solar particle event‏‎ (2 revisions)
  151. Effective dose equivalent‏‎ (2 revisions)
  152. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  153. Acceptance test‏‎ (2 revisions)
  154. Gastrulation‏‎ (2 revisions)
  155. Working level‏‎ (2 revisions)
  156. OLINDA/EXM‏‎ (2 revisions)
  157. Habitual mouth breather‏‎ (2 revisions)
  158. Annihilation photons‏‎ (2 revisions)
  159. Particle radiance‏‎ (2 revisions)
  160. Hyperfractionation‏‎ (2 revisions)
  161. Bone marrow‏‎ (2 revisions)
  162. Protection strategy‏‎ (2 revisions)
  163. Radiation source‏‎ (2 revisions)
  164. Cohort study‏‎ (2 revisions)
  165. Radiosensitiser‏‎ (2 revisions)
  166. DRL value‏‎ (2 revisions)
  167. Rehabilitation of living conditions‏‎ (2 revisions)
  168. Right to know‏‎ (2 revisions)
  169. Incidence‏‎ (2 revisions)
  170. Solar wind‏‎ (2 revisions)
  171. Epithelium‏‎ (2 revisions)
  172. Target tissue‏‎ (2 revisions)
  173. Expanded and aligned radiation field‏‎ (2 revisions)
  174. Tolerability‏‎ (2 revisions)
  175. Medical exposure‏‎ (2 revisions)
  176. Naturally occurring radioactive material‏‎ (2 revisions)
  177. Adventitious‏‎ (2 revisions)
  178. Working level month‏‎ (2 revisions)
  179. Habitual nose breather‏‎ (2 revisions)
  180. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  181. Background dose (rate)‏‎ (2 revisions)
  182. Radiosensitivity, cellular‏‎ (2 revisions)
  183. Containment‏‎ (2 revisions)
  184. Rigidity‏‎ (2 revisions)
  185. Dose-length product‏‎ (2 revisions)
  186. Security‏‎ (2 revisions)
  187. Incident‏‎ (2 revisions)
  188. Intermediate level waste‏‎ (2 revisions)
  189. Stenosis‏‎ (2 revisions)
  190. Equieffective dose‏‎ (2 revisions)
  191. Local DRL‏‎ (2 revisions)
  192. Member of the public‏‎ (2 revisions)
  193. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  194. Unattached fraction‏‎ (2 revisions)
  195. Necrosis‏‎ (2 revisions)
  196. Patient entrance reference point‏‎ (2 revisions)
  197. Hypoplasia‏‎ (2 revisions)
  198. Backscatter detection system‏‎ (2 revisions)
  199. Potential recoverability correction factor‏‎ (2 revisions)
  200. Bradycardia‏‎ (2 revisions)
  201. Protective action guide‏‎ (2 revisions)
  202. Radiation worker‏‎ (2 revisions)
  203. Detriment‏‎ (2 revisions)
  204. Dose-rate effect‏‎ (2 revisions)
  205. Inclusiveness‏‎ (2 revisions)
  206. Source-related‏‎ (2 revisions)
  207. Internal conversion electron‏‎ (2 revisions)
  208. Electron-capture decay‏‎ (2 revisions)
  209. LD 50/30‏‎ (2 revisions)
  210. Telangiectasia‏‎ (2 revisions)
  211. Track structure‏‎ (2 revisions)
  212. Mendelian diseases‏‎ (2 revisions)
  213. Accreditation‏‎ (2 revisions)
  214. Neurological syndrome‏‎ (2 revisions)
  215. Genomic integrity‏‎ (2 revisions)
  216. Occupational exposure‏‎ (2 revisions)
  217. Hazard‏‎ (2 revisions)
  218. Peak skin dose‏‎ (2 revisions)
  219. Bragg peak‏‎ (2 revisions)
  220. Radioactive dispersion device‏‎ (2 revisions)
  221. Radon: Units of Measure‏‎ (2 revisions)
  222. Coronary heart disease‏‎ (2 revisions)
  223. Reference air kerma‏‎ (2 revisions)
  224. Decay constant‏‎ (2 revisions)
  225. Self-help protection‏‎ (2 revisions)
  226. Individual-related‏‎ (2 revisions)
  227. Dose of record Hp (10)‏‎ (2 revisions)
  228. Electrophysiology‏‎ (2 revisions)
  229. Storage‏‎ (2 revisions)
  230. Transfer compartment‏‎ (2 revisions)
  231. Mitigation‏‎ (2 revisions)
  232. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  233. Action Level‏‎ (2 revisions)
  234. Upper reference levels‏‎ (2 revisions)
  235. Neurovascular syndrome‏‎ (2 revisions)
  236. Health Surveillance‏‎ (2 revisions)
  237. Pelagic‏‎ (2 revisions)
  238. Basal cell‏‎ (2 revisions)
  239. Practical radiological protection culture‏‎ (2 revisions)
  240. Branching fraction‏‎ (2 revisions)
  241. Chronic exposure‏‎ (2 revisions)
  242. Radioactive source‏‎ (2 revisions)
  243. Colony‏‎ (2 revisions)
  244. Cosmic Radiation in Aviation‏‎ (2 revisions)
  245. Decommissioning‏‎ (2 revisions)
  246. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  247. Dose-threshold‏‎ (2 revisions)
  248. Individual decontamination‏‎ (2 revisions)
  249. Subcutaneous tissue‏‎ (2 revisions)
  250. Low dose rate‏‎ (2 revisions)
  251. Exposure, external or internal‏‎ (2 revisions)
  252. Graft vs host disease‏‎ (2 revisions)
  253. Air-kerma, incident‏‎ (2 revisions)
  254. Heliosphere‏‎ (2 revisions)
  255. Qualified expert‏‎ (2 revisions)
  256. Class SR-0 gases‏‎ (2 revisions)
  257. Radioactive substance‏‎ (2 revisions)
  258. Reference biokinetic model‏‎ (2 revisions)
  259. Decontamination‏‎ (2 revisions)
  260. Relocation‏‎ (2 revisions)
  261. Diastasis‏‎ (2 revisions)
  262. Risk coefficient‏‎ (2 revisions)
  263. Individual monitoring‏‎ (2 revisions)
  264. Dose per unit intake coefficient‏‎ (2 revisions)
  265. Source term‏‎ (2 revisions)
  266. Emergency‏‎ (2 revisions)
  267. Latent time/period or latency interval‏‎ (2 revisions)
  268. Low level waste‏‎ (2 revisions)
  269. Exposure (in the context of inhalation)‏‎ (2 revisions)
  270. Transfer rate‏‎ (2 revisions)
  271. Multi-detector computed tomography‏‎ (2 revisions)
  272. Fractionation and dose delivery patterns‏‎ (2 revisions)
  273. Percutaneous coronary intervention‏‎ (2 revisions)
  274. Prevailing circumstances‏‎ (2 revisions)
  275. Broad beam therapy irradiation technique‏‎ (2 revisions)
  276. Class SR-1 gases‏‎ (2 revisions)
  277. Committed effective dose‏‎ (2 revisions)
  278. Radon Recommendations for Authorities‏‎ (2 revisions)
  279. Cost-benefit analysis‏‎ (2 revisions)
  280. Reference individual‏‎ (2 revisions)
  281. Decontamination factor‏‎ (2 revisions)
  282. Remedial action‏‎ (2 revisions)
  283. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  284. Dose rate‏‎ (2 revisions)
  285. Intervention Level‏‎ (2 revisions)
  286. Emergency exposure situation‏‎ (2 revisions)
  287. Substantial radiation dose level‏‎ (2 revisions)
  288. Erythropoietin‏‎ (2 revisions)
  289. ALARA‏‎ (2 revisions)
  290. Transforming growth factor‏‎ (2 revisions)
  291. Hierarchical tissues‏‎ (2 revisions)
  292. Area monitoring‏‎ (2 revisions)
  293. Pericarditis‏‎ (2 revisions)
  294. Benthic‏‎ (2 revisions)
  295. Principle of application of dose limits‏‎ (2 revisions)
  296. Bronchial region‏‎ (2 revisions)
  297. Class SR-2 gases‏‎ (2 revisions)
  298. Radioactivity‏‎ (2 revisions)
  299. Committed equivalent dose‏‎ (2 revisions)
  300. Radon Recommendations for Workplaces‏‎ (2 revisions)
  301. Reference level‏‎ (2 revisions)
  302. Remediation‏‎ (2 revisions)
  303. Dichotomous‏‎ (2 revisions)
  304. Risk of Exposure to Radon‏‎ (2 revisions)
  305. Dose rate effectiveness factor‏‎ (2 revisions)
  306. South Atlantic anomaly‏‎ (2 revisions)
  307. Interventional procedure‏‎ (2 revisions)
  308. Emergency plan‏‎ (2 revisions)
  309. Ethics‏‎ (2 revisions)
  310. Lymphatic system‏‎ (2 revisions)
  311. Multiplicative risk projection model‏‎ (2 revisions)
  312. Activity‏‎ (2 revisions)
  313. High level waste‏‎ (2 revisions)
  314. Clearance‏‎ (2 revisions)
  315. Deontological Ethics‏‎ (2 revisions)
  316. Repopulation‏‎ (2 revisions)
  317. Differentiation‏‎ (2 revisions)
  318. Routine monitoring‏‎ (2 revisions)
  319. ICRPædia Guide to Radon‏‎ (2 revisions)
  320. Special (non-routine) monitoring‏‎ (2 revisions)
  321. Lifetime risk‏‎ (2 revisions)
  322. Macrophage colony stimulating factor‏‎ (2 revisions)
  323. Beta-minus decay‏‎ (2 revisions)
  324. Clearance level‏‎ (2 revisions)
  325. Radiographer‏‎ (2 revisions)
  326. Representative organism (non-human biota)‏‎ (2 revisions)
  327. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  328. Dose constraint‏‎ (2 revisions)
  329. Early normal tissue responses‏‎ (2 revisions)
  330. Threshold dose for tissue reactions‏‎ (2 revisions)
  331. Magnetosphere‏‎ (2 revisions)
  332. Exposure situation‏‎ (2 revisions)
  333. Transmission detection system‏‎ (2 revisions)
  334. Multistage tumorigenesis‏‎ (2 revisions)
  335. Non-sphericity parameter‏‎ (2 revisions)
  336. Growth factor‏‎ (2 revisions)
  337. Alimentary tract transfer factor‏‎ (2 revisions)
  338. Pharynx‏‎ (2 revisions)
  339. Beta-plus decay‏‎ (2 revisions)
  340. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  341. Cumulative dose‏‎ (2 revisions)
  342. Representative person‏‎ (2 revisions)
  343. Safety‏‎ (2 revisions)
  344. Dose conversion coefficient‏‎ (2 revisions)
  345. Edema‏‎ (2 revisions)
  346. Specific effective energy‏‎ (2 revisions)
  347. Limitation of dose‏‎ (2 revisions)
  348. Excess relative risk‏‎ (2 revisions)
  349. Marrow cellularity‏‎ (1 revision)
  350. Multitarget equation‏‎ (1 revision)
  351. Acute exposure‏‎ (1 revision)
  352. Allometry‏‎ (1 revision)
  353. Pilomatricoma‏‎ (1 revision)
  354. ICRP Publication 102‏‎ (1 revision)
  355. ICRP Publication 116‏‎ (1 revision)
  356. Radiation-induced secondary malignancy‏‎ (1 revision)
  357. ICRP Publication 130‏‎ (1 revision)
  358. Radiological attack‏‎ (1 revision)
  359. ICRP Publication 145‏‎ (1 revision)
  360. Reactive oxygen species‏‎ (1 revision)
  361. ICRP Publication 2‏‎ (1 revision)
  362. Reference worker‏‎ (1 revision)
  363. ICRP Publication 30 (Part 3)‏‎ (1 revision)
  364. Derived consideration reference level‏‎ (1 revision)
  365. ICRP Publication 92‏‎ (1 revision)
  366. ICRP Publication 40‏‎ (1 revision)
  367. ICRP Publication 55‏‎ (1 revision)
  368. Dose conversion convention‏‎ (1 revision)
  369. Informed consent‏‎ (1 revision)
  370. ICRP Publication 7‏‎ (1 revision)
  371. Spongiosa‏‎ (1 revision)
  372. ICRP Publication 84‏‎ (1 revision)
  373. Exclusion‏‎ (1 revision)
  374. Time-resolved computed tomography‏‎ (1 revision)
  375. Mutation component‏‎ (1 revision)
  376. Waste management‏‎ (1 revision)
  377. Normal tissue complication probability‏‎ (1 revision)
  378. Biological half-life‏‎ (1 revision)
  379. ICRP Publication 117‏‎ (1 revision)
  380. ICRP Publication 131‏‎ (1 revision)
  381. Radiological controlled area‏‎ (1 revision)
  382. ICRP Publication 146‏‎ (1 revision)
  383. Concentration ratio‏‎ (1 revision)
  384. ICRP Publication 20‏‎ (1 revision)
  385. Referrer‏‎ (1 revision)
  386. ICRP Publication 30 (Part 4)‏‎ (1 revision)
  387. Derived investigation level‏‎ (1 revision)
  388. ICRP Publication 93‏‎ (1 revision)
  389. ICRP Publication 41‏‎ (1 revision)
  390. Directional dose equivalent‏‎ (1 revision)
  391. ICRU 4-element tissue‏‎ (1 revision)
  392. ICRP Publication 56‏‎ (1 revision)
  393. Dose conversion factor‏‎ (1 revision)
  394. ICRP Publication 70‏‎ (1 revision)
  395. Effect modifier‏‎ (1 revision)
  396. ICRP Publication 85‏‎ (1 revision)
  397. Endosteum‏‎ (1 revision)
  398. System of radiological protection‏‎ (1 revision)
  399. Treatment preparation in radiotherapy‏‎ (1 revision)
  400. Notification value‏‎ (1 revision)
  401. Other (systemic) tissues‏‎ (1 revision)
  402. Human Alimentary Tract Model‏‎ (1 revision)
  403. ICRP Publication 104‏‎ (1 revision)
  404. Biomarker‏‎ (1 revision)
  405. ICRP Publication 132‏‎ (1 revision)
  406. Clonogenic surviving fraction‏‎ (1 revision)
  407. ICRP Publication 147‏‎ (1 revision)
  408. Cone beam computed tomography‏‎ (1 revision)
  409. ICRP Publication 21‏‎ (1 revision)
  410. Region‏‎ (1 revision)
  411. ICRP Publication 30 (Supplement A to Part 3)‏‎ (1 revision)
  412. Derived limit‏‎ (1 revision)
  413. ICRP Publication 94‏‎ (1 revision)
  414. ICRP Publication 42‏‎ (1 revision)
  415. ICRU sphere‏‎ (1 revision)
  416. ICRP Publication 57‏‎ (1 revision)
  417. ICRP Publication 71‏‎ (1 revision)
  418. ICRP Publication 86‏‎ (1 revision)
  419. Mean glandular dose‏‎ (1 revision)
  420. Absorption Type‏‎ (1 revision - redirect page)
  421. Trophic level‏‎ (1 revision)
  422. Additional dose‏‎ (1 revision)
  423. Nuclear medicine‏‎ (1 revision)
  424. Ambient dose equivalent‏‎ (1 revision)
  425. Human Respiratory Tract Model‏‎ (1 revision)
  426. Automatic exposure control‏‎ (1 revision)
  427. Pooled analysis‏‎ (1 revision)
  428. ICRP Publication 105‏‎ (1 revision)
  429. ICRP Publication 119‏‎ (1 revision)
  430. Radiation risk‏‎ (1 revision)
  431. ICRP Publication 133‏‎ (1 revision)
  432. ICRP Publication 148‏‎ (1 revision)
  433. ICRP Publication 22‏‎ (1 revision)
  434. Regional diagnostic reference levels‏‎ (1 revision)
  435. ICRP Publication 30 (Supplement B to Part 3)‏‎ (1 revision)
  436. Derived reference level‏‎ (1 revision)
  437. ICRP Publication 95‏‎ (1 revision)
  438. ICRP Publication 43‏‎ (1 revision)
  439. Disposal facility‏‎ (1 revision)
  440. Sealed source‏‎ (1 revision)
  441. ICRP Publication 58‏‎ (1 revision)
  442. Solar flare‏‎ (1 revision)
  443. ICRP Publication 72‏‎ (1 revision)
  444. ICRP Publication 87‏‎ (1 revision)
  445. Linear dose response‏‎ (1 revision)
  446. 1928 Recommendations‏‎ (1 revision)
  447. Tissue reaction‏‎ (1 revision)
  448. Measured quantity‏‎ (1 revision)
  449. Tumour suppressor gene‏‎ (1 revision)
  450. National DRL‏‎ (1 revision)
  451. Additive risk projection model‏‎ (1 revision)
  452. Oxygen enhancement ratio‏‎ (1 revision)
  453. Population risk‏‎ (1 revision)
  454. ICRP Publication 106‏‎ (1 revision)
  455. ICRP Publication 12‏‎ (1 revision)
  456. ICRP Publication 134‏‎ (1 revision)
  457. Cobblestone area forming cell assay‏‎ (1 revision)
  458. ICRP Publication 149‏‎ (1 revision)
  459. ICRP Publication 23‏‎ (1 revision)
  460. DRL quantity‏‎ (1 revision)
  461. Registry‏‎ (1 revision)
  462. ICRP Publication 30 (Supplement to Part 1)‏‎ (1 revision)
  463. Designated area‏‎ (1 revision)
  464. ICRP Publication 96‏‎ (1 revision)
  465. ICRP Publication 44‏‎ (1 revision)
  466. Distribution coefficient‏‎ (1 revision)
  467. Secondary radiation‏‎ (1 revision)
  468. ICRP Publication 59‏‎ (1 revision)
  469. Intake‏‎ (1 revision)
  470. ICRP Publication 73‏‎ (1 revision)
  471. Standard-size adult‏‎ (1 revision)
  472. ICRP Publication 88‏‎ (1 revision)
  473. Epigenetic effects‏‎ (1 revision)
  474. Exogenous excretion‏‎ (1 revision)
  475. 1931 Recommendations‏‎ (1 revision)
  476. National radon survey‏‎ (1 revision)
  477. Adenoma‏‎ (1 revision)
  478. Potential alpha energy concentration‏‎ (1 revision)
  479. ICRP Publication 107‏‎ (1 revision)
  480. ICRP Publication 120‏‎ (1 revision)
  481. Carers and comforters‏‎ (1 revision)
  482. ICRP Publication 135‏‎ (1 revision)
  483. ICRP Publication 15‏‎ (1 revision)
  484. Redox‏‎ (1 revision)
  485. ICRP Publication 24‏‎ (1 revision)
  486. ICRP Publication 30 (Supplement to Part 2)‏‎ (1 revision)
  487. Detector quantum efficiency‏‎ (1 revision)
  488. ICRP Publication 97‏‎ (1 revision)
  489. ICRP Publication 45‏‎ (1 revision)
  490. Secretory cells‏‎ (1 revision)
  491. ICRP Publication 6‏‎ (1 revision)
  492. Intensity-modulated radiotherapy‏‎ (1 revision)
  493. ICRP Publication 74‏‎ (1 revision)
  494. Stem cell‏‎ (1 revision)
  495. Kerma approximation‏‎ (1 revision)
  496. ICRP Publication 89‏‎ (1 revision)
  497. 1934 Recommendations‏‎ (1 revision)
  498. Access control‏‎ (1 revision)
  499. Typical value‏‎ (1 revision)
  500. General Information: Radon‏‎ (1 revision - redirect page)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"